About: Addictovigilance contribution during COVID-19 epidemic and lockdown in France

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Addictovigilance contribution during COVID-19 epidemic and lockdown in France Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Addictovigilance contribution during COVID-19 epidemic and lockdown in France
Creator	Micallef, Joëlle Boucher, Alexandra Bouquet, Emilie Chaouachi, Leila Chevalier, Cécile Daveluy, Amelie Deheul, Sylvie Eiden, Céline Fouilhé, Nathalie Fournier-Choma, Chistine Frauger, Elisabeth Gibaja, Valerie Guerlais, Marylène Jouanjus, Emilie Joëlle, Helene Lapeyre-Mestre, Maryse Le Boisselier, Reynald Mallaret, Michel Miremont, Ghada Network, French Peyrière, Helene Roussin, Anne Tournebize, Juliana
source	Elsevier; Medline; PMC
abstract	Abstract Addictovigilance is a safety monitoring targeted at substances with potential for abuse and dependence. This vigilance was involved during the period of COVID-19 epidemic due to the significant changes in access to drugs and psychological disruption caused by the pandemic and lockdown. This article aims to present the different steps implemented by the French Addictovigilance network in collaboration with the French Health authorities from March to May 2020, including monitoring of potential harmful events, and scientific communication. The first events were identified through the continuity of the networking between the French addictovigilance centres and their partners: community pharmacies, general practitioners, specialized structures and emergency wards. As soon as the lockdown began, first cases of overdoses (lethal or not) were reported with opioids, mainly with methadone, and other opioids (heroin, oxycodone, tramadol or antitussive codeine). Lockdown-related noteworthy events consisted in clinical cases or other relevant information for which lockdown clearly played an important role : among the many substances identified at least once, pregabalin, benzodiazepines, cannabis, cocaine and nitrous oxide were the most significant in terms of prevalence, seriousness or particularly specific to the lockdown context. Despite significant decrease in the activity and travel limited to vital needs, community pharmacies continued to identify falsified prescriptions in this period, highlighting an increase in suspicious requests for pregabalin, codeine and tramadol. In parallel, the French addictovigilance network continued its communications efforts in the period, issuing a newsletter on tramadol, a press release on methadone and naloxone, and participating in the COVID-19 frequently asked questions (FAQs) of the French Society of Pharmacology and Therapeutic website (https://sfpt-fr.org/covid19 ). COVID-19 epidemic has been an important challenge for addictovigilance, and has proved that this monitoring is highly essential for alerting health professionals and health authorities to points of vigilance in the field of psychoactive substances.
has issue date	2020-06-23(xsd:dateTime)
bibo:doi	10.1016/j.therap.2020.06.006
bibo:pmid	32660776
has license	els-covid
sha1sum (hex)	2c2614f0dca663605036cdd2bbac3112cf0ac94f
schema:url	https://doi.org/10.1016/j.therap.2020.06.006
resource representing a document's title	Addictovigilance contribution during COVID-19 epidemic and lockdown in France
has PubMed Central identifier	PMC7309935
has PubMed identifier	32660776
schema:publication	Therapie
resource representing a document's body	covid:2c2614f0dca663605036cdd2bbac3112cf0ac94f#body_text
is schema:about of	named entity 'cannabis' named entity 'community pharmacies' named entity 'This' named entity 'identify' named entity 'structures' named entity 'tramadol' named entity 'French Society' named entity 'PHARMACOLOGY' named entity 'THEIR' named entity 'PRESCRIPTIONS' named entity 'REPORTED' named entity 'DECREASE' named entity 'COVID-19 EPIDEMIC' named entity 'PERIOD' named entity 'PSYCHOLOGICAL' named entity 'PREVALENCE' named entity 'COLLABORATION' named entity 'DEPENDENCE' named entity 'context' named entity 'identified' named entity 'centres' named entity 'French' named entity 'epidemic' named entity 'authorities' named entity 'highlighting' named entity 'general practitioners' named entity 'cocaine' named entity 'wards' named entity 'cases' named entity 'benzodiazepines' named entity 'disruption' named entity 'codeine' named entity 'lockdown' named entity 'pregabalin' named entity 'nitrous oxide' named entity 'codeine' named entity 'opioids' named entity 'benzodiazepines' named entity 'codeine' named entity 'general practitioners' named entity 'methadone' named entity 'epidemic' named entity 'oxycodone' named entity 'opioid medications' named entity 'ASOS' named entity 'France' named entity 'opioid analgesics' named entity 'epilepsy' named entity 'psychotropic' named entity 'illicit substances' named entity 'medical prescription' named entity 'methadone' named entity 'tramadol' named entity 'cocaine' named entity 'overdose' named entity 'methadone' named entity 'hydroxyzine' named entity 'pharmacies' named entity 'opioid'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software